Roche Canada confirms Gazyva (obinutuzumab) received positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritis
[출처/시간] Briefing.com - 10:01 AM ET, 05/22/2026 This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. This positive recommendation expands the pathway to patient access, following Health Canada's authorization in January 2026.
[출처/시간] Briefing.com - 10:01 AM ET, 05/22/2026
This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. This positive recommendation expands the pathway to patient access, following Health Canada's authorization in January 2026.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
